A partnership has been formed between Chai Discovery, an AI firm specializing in molecule design, and argenx, a prominent immunology innovation company based in San Francisco. Under this agreement, argenx will utilize Chai's AI platform for de novo antibody discovery targeting therapeutic objectives. Renowned for its effective antibody engines, argenx merges substantial immunological knowledge with advanced antibody engineering techniques. This collaboration marks a significant step in advancing research and development within the biotechnology sector.
